Editor's Note
Welcome to the seventh issue of Xtalks Clinical Edge, highlighting the science and leadership driving progress across clinical research!
This edition features 12 conversations with leaders advancing clinical research across immunology, respiratory medicine, neurology, women’s health, oncology and diagnostics. Together, these stories reflect a shared focus on translating evolving biology into more precise trials, smarter endpoints and, ultimately, better outcomes for patients.
Several features highlight how trial design is adapting to real-world disease complexity. Boehringer Ingelheim examines the urgent need to improve awareness, earlier diagnosis and disease characterization in idiopathic pulmonary fibrosis (IPF), alongside more patient-centered clinical research approaches. In respiratory medicine, Connect Biopharma discusses why acute asthma and chronic obstructive pulmonary disease (COPD) exacerbations remain difficult to study in emergency settings.
Across immunology and inflammation, a common theme emerges: moving upstream in biology to achieve more durable control. InflaRx shares how complement-targeted strategies are expanding beyond rare diseases into broader inflammatory conditions, while AnaptysBio explores cell-targeted immunotherapies aimed to rebalance immune systems, not just suppress single cytokines.
We also highlight how biomarkers and regulatory pathways are reshaping the path to diagnosis and innovation. Augurex takes on the long-standing diagnostic delay in axial spondyloarthritis with an emerging anti-14-3-3η biomarker program supported by FDA Breakthrough Device Designation, an example of how precision diagnostics can move care upstream and change the patient journey.
In data-driven medicine and global access, Takeda outlines how real-world evidence (RWE), patient insights and human-focused AI are influencing evidence generation, trial inclusivity and access strategies, especially in rare diseases where traditional trial models can fall short.
This issue also examines disease areas where scientific complexity, therapeutic delivery and meaningful measurement continue to pose major challenges. Dompé discusses optic neuropathies and what the FDA’s Commissioner's National Priority Voucher (CNPV) program could signal for accelerating development in neuro-ophthalmology. Klotho Neurosciences addresses the complexities of neurodegeneration research, from biomarker interpretation to manufacturing and delivery challenges in gene-based approaches. DiaMedica explores the difficulty of developing therapies for ischemic diseases such as stroke and preeclampsia, where safety, timing and meaningful endpoints are paramount. Medtronic Neurovascular examines persistent gaps in stroke care, from access and awareness to global disparities, and how innovation and partnerships are helping address these challenges.
In oncology, Atossa Therapeutics reflects on how endocrine therapy in ER-positive breast cancer is evolving, with growing emphasis on long-term tolerability, prevention and more adaptive trial models that better match real-world biology.
Finally, our dermatology feature with Galderma broadens the lens on skin disease, highlighting itch biology, sensitive skin heterogeneity and the increasing role of long-term and real-world data (RWD) in understanding disease burden beyond visible symptoms.
At Xtalks Clinical Edge, our mission remains clear: to highlight the people, science and ideas moving clinical research forward.
We hope you enjoy this edition and join us again for our next issue in May 2026!